Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer

International Journal of Clinical Practice

Volumn 65, Issue 4, 2011, Pages 472-478

  Clemens, Katri Elina ^a,b,c   Quednau, I ^a,b,c   Klaschik, E ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Malteser Hospital Bonn/Rhein Sieg   (Germany)

^c MediClin Robert Janker Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; HYDROMORPHONE; LAXATIVE; MORPHINE; MORPHINE DERIVATIVE; NALOXONE PLUS OXYCODONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; PICOSULFATE SODIUM; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ARTICLE; BOWEL FUNCTION INDEX; BRISTOL STOOL FORM SCALE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION HABIT; DIARRHEA; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE FUNCTION; MALE; NAUSEA; OPEN STUDY; PATIENT GLOBAL IMPRESSION OF CHANGE SCALE; PATIENT SATISFACTION; PRIORITY JOURNAL; RATING SCALE; TABLET;

AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC PAIN; CONSTIPATION; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NEOPLASMS; OXYCODONE; TABLETS;

EID: 79952743402     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02634.x     Document Type: Article

References (35)

1. Colvin L, Forbes K, Fallon M. Difficult pain. BMJ 2006; 332: 1081-3.
2. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 353: 1695-700. (Pubitemid 29224537)
3. World Health Organization. Cancer Pain Relief, 2nd edn. Report of WHO Expert Committee. Geneva: WHO, 1996.
4. Bruera E, Macmillan K, Hanson J, MacDonald RN. Palliative care in a cancer center: results in 1984 versus 1987. J Pain Symptom Manage 1990; 5: 1-5.
5. Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer 1998; 6: 356-64. (Pubitemid 28337126)
6. Vainio A, Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Symptom Manage 1996; 12: 3-10. (Pubitemid 26187518)
7. Fallon MT. Constipation in cancer patients: prevalence, pathogenesis, and cost-related issues. Eur J Pain 1999; 3 (Suppl.): 3-7. (Pubitemid 29292684)
8. Twycross R, Diarrhoea. In: Twycross RG, Lack SA (eds). Control of Alimentary Symptoms in Far Advanced Cancer. London: Churchill Livingstone, 1986: 166-229.
9. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004; 11 (Suppl. 3): 3-9. (Pubitemid 38756665)
10. Avila JG. Pharmacologic treatment of constipation in cancer patients. Cancer Control 2004; 11 (Suppl. 3): 10-8. (Pubitemid 38756666)
11. Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage 2008; 35: 103-13. (Pubitemid 350299099)
12. Clemens KE, Klaschik E. Management of constipation in palliative care patients. Curr Opin Support Palliat Care 2008; 2: 22-7.
13. Clemens KE, Klaschik E. Managing nausea, emesis and constipation in palliative care. Dtsch Arztebl 2007; 104: 269-78. (Pubitemid 46338209)
14. Drossmann DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 1990; 3: 159-72.
15. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 649-71. (Pubitemid 36408072)
16. Nozaki C, Saitoh A, Tamura N, Kamei J. Antinociceptive effect of oxycodone in diabetic mice. Eur J Pharmacol 2005; 524: 75-9. (Pubitemid 41606816)
17. Meissner W, Leyendecker P, Mueller-Lissner S et al. A randomised controlled trial with prolongedrelease oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009; 13: 56-64.
18. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-4. (Pubitemid 27382038)
19. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12: 371-83.
20. Chang L. From Rome to Los Angeles - The Rome III criteria for the functional GI disorders. Gastroenterology 2006; 130: 1480-91.
21. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182: 11S-8S.
22. Berde C, Nurko S. Opioid side effects - mechanism-based therapy. N Engl Med 2008; 358: 2400-2. (Pubitemid 351749167)
23. Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 1998; 12: 375-82. (Pubitemid 28454405)
24. Wirz S, Klaschik E. Management of constipation in palliative care patients undergoing opioid therapy: is polyethylene glycol an option? Am J Hosp Palliat Care 2005; 22: 375-81. (Pubitemid 41432865)
25. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004; 361: 192-5. (Pubitemid 38609249)
26. Kalso E. Oxycodone. J Pain Symptom Manage 2005; 29: 47-56.
27. Mandema JW, Kaiko RF, Oshlack B et al. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996; 42: 747-56. (Pubitemid 26417617)
28. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002; 23: 48-53. (Pubitemid 34093880)
29. Meissner W, Schmidt U, Hartmann M et al. Oral naloxone reverses opioid-associated constipation. Pain 2000; 84: 105-9.
30. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996; 10: 135-44. (Pubitemid 26110994)
31. Clemens KE, Mikus G. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain. Expert Opin Pharmacother 2010; 11: 297-310.
32. Colluzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol 2005; 71:451-60.
33. Vondrackova D, Leyendecker P, Meissner W et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008; 9: 1144-54.
34. Simpson K, Leyendecker P, Hopp M et al. A randomized double-blind trial of combined prolonged release oxycodone and naloxone in patients with moderate-to severe non-cancer pain. Curr Med Res Opin 2008; 24: 3503-12.
35. Löwenstein O, Leyendecker P, Hopp M et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009; 10: 531-43.